Valbenazine is a vesicular monoamine transporter 2 inhibitor indicated for the treatment of adults with - tardive dyskinesia. It is available as capsules and kits for oral use. MedsAcross supplies Valbenazine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
INGREZZA and INGREZZA SPRINKLE are indicated for the treatment of adults with: - tardive dyskinesia. - chorea associated with Huntington’s disease. INGREZZA and INGREZZA SPRINKLE are vesicular monoamine transporter 2 (VMAT2) inhibitors indicated for the treatment of adults with: - tardive dyskinesia. - chorea associated with Huntington’s disease.
Source: US FDA prescribing information
The mechanism of action of valbenazine for the treatment of tardive dyskinesia and chorea in patients with Huntington’s disease is unclear, but is thought to be mediated through the reversible inhibition of vesicular monoamine transporter 2 (VMAT2), a transporter that regulates monoamine uptake from the cytoplasm to the synaptic vesicle for storage and release.
Source: US FDA prescribing information
Tardive dyskinesia: The initial dosage is 40 mg once daily. After one week, increase the dose to the recommended dosage of 80 mg once daily. Chorea associated with Huntington’s disease: The initial dosage is 40 mg once daily. Increase the dose in 20 mg increments every two weeks to the recommended dosage of 80 mg once daily. 40 mg or 60 mg once daily may be considered depending on response and tolerability. Can be taken with or without food. INGREZZA SPRINKLE may be opened and sprinkled over soft food (do not use milk or drinking water). INGREZZA SPRINKLE may be swallowed whole with water. Do not crush or chew. The recommended dosage for patients with moderate or severe hepatic impairment is 40 mg once daily. The recommended dosage for known CYP2D6 poor metabolizers is 40 mg once daily.
Source: US FDA prescribing information
INGREZZA and INGREZZA SPRINKLE are contraindicated in patients with a history of hypersensitivity to valbenazine or any components of INGREZZA or INGREZZA SPRINKLE. Rash, urticaria, and reactions consistent with angioedema (e.g., swelling of the face, lips, and mouth) have been reported with use of INGREZZA. Known hypersensitivity to valbenazine or any components of INGREZZA or INGREZZA SPRINKLE.
Source: US FDA prescribing information
Boxed warning (depression and suicidal ideation and behavior in patients with huntington’s disease vmat2): inhibitors, including INGREZZA and INGREZZA SPRINKLE, can increase the risk of depression and suicidal thoughts and behavior in patients with Huntington’s disease. Anyone considering the use of INGREZZA or INGREZZA SPRINKLE must balance the risks of depression and suicidal ideation and behavior with the clinical need for treatment of chorea. Depression and suicidal ideation and behavior in patients with Huntington’s disease. Hypersensitivity, including angioedema may occur. Discontinue if this occurs. Somnolence/sedation: May impair patient’s ability to drive or operate hazardous machinery. QT Prolongation: May cause an increase in QT interval. Avoid use in patients with congenital long QT syndrome or with arrhythmias associated with a prolonged QT interval.
Source: US FDA prescribing information
The following clinically significant adverse reactions are discussed in more detail in other sections of the labeling: Depression and Suicidal Ideation and Behavior in Patients with Huntington’s Disease Hypersensitivity Reactions Somnolence and Sedation QT Prolongation Neuroleptic Malignant Syndrome (NMS) Parkinsonism Most common adverse reaction (≥5% and twice the rate of placebo): - Tardive dyskinesia: somnolence. - Chorea associated with Huntington’s disease: somnolence/lethargy/sedation, urticaria, rash, insomnia.
Source: US FDA prescribing information
Dose adjustments due to drug interactions: Factors Dose Adjustments for INGREZZA and INGREZZA SPRINKLE Use of MAOIs with INGREZZA or INGREZZA SPRINKLE Avoid concomitant use with MAOIs. Use of strong CYP3A4 inducers with INGREZZA or INGREZZA SPRINKLE Concomitant use is not recommended. Use of strong CYP3A4 inhibitors with INGREZZA or INGREZZA SPRINKLE Recommended dosage is 40 mg once daily. Use of strong CYP2D6 inhibitors with INGREZZA or INGREZZA SPRINKLE Recommended dosage is 40 mg once daily.
Source: US FDA prescribing information
Storage INGREZZA: Store at 15°C to 30°C (59°F to 86°F). INGREZZA SPRINKLE: Store at 20°C to 25°C (68°F to 77°F). Excursions permitted between 15°C and 30°C (59°F and 86°F). Protect from moisture.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
7 presentations of Valbenazine, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Ingrezza kitOral | Neurocrine Biosciences | US FDA | Available on request |
| Ingrezza 40 mg capsuleOral | Neurocrine Biosciences | US FDA | Available on request |
| Ingrezza 60 mg capsuleOral | Neurocrine Biosciences | US FDA | Available on request |
| Ingrezza 80 mg capsuleOral | Neurocrine Biosciences | US FDA | Available on request |
| INGREZZA Sprinkle 40 mg capsuleOral | Neurocrine Biosciences | US FDA | Available on request |
| INGREZZA Sprinkle 60 mg capsuleOral | Neurocrine Biosciences | US FDA | Available on request |
| INGREZZA Sprinkle 80 mg capsuleOral | Neurocrine Biosciences | US FDA | Available on request |
2 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 11 April 2017 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Conditions linked to Valbenazine in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 7 presentations of Valbenazine and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 2 brand names for Valbenazine, including Ingrezza, INGREZZA Sprinkle.
Yes. The US FDA first approved Valbenazine on 11 April 2017, according to Drugs@FDA.
No listed presentation of Valbenazine is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Valbenazine is classified under ATC code N07XX13 (Valbenazine).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.